youtube_live
Q3 2026 earnings • released • EPS miss -4.85% • Revenue beat +35.08%
See resultschevron_right
IDYA:NASDAQ
Ideaya Biosciences Inc
$31.66
arrow_upward
+1.05%(+0.33) 1D
Nov 4, 3:10:04 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IDYA...
Open
$31.97
High
$32.30
Low
$31.37
Mkt. cap
3.05B
Avg. vol.
946.55K
Volume
704.00K
52-wk high
$42.68
52-wk low
$26.81
EPS
-$1.94
Beta
0.08
Shares outstanding
96.49M
No. of employees
145
Open
$31.97
High
$32.30
Low
$31.37
Mkt. cap
3.05B
Avg. vol.
946.55K
Volume
704.00K
52-wk high
$42.68
52-wk low
$26.81
EPS
-$1.94
Beta
0.08
Shares outstanding
96.49M
No. of employees
145
News stories
From web sources and news partners
GuruFocus
·
2 hours ago
IDYA Maintains Outperform Rating -- Price Target Lowered to $45
Yahoo Finance
·
9 hours ago
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
Investing.com
·
1 day ago
Truist cuts Ideaya Biosciences stock price target on revised estimates
About Ideaya Biosciences Inc
CEO-
Employees145
Founded2015
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Industry-
Websiteideayabio.com
Analyst ratings
Based on 13 analysts giving stock ratings to IDYA in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for IDYA in the last 3 months.
Highest
Current $31.66
$65.00 (+105.31%)
Average
$51.92 (+63.99%)
Lowest
$42.00 (+32.66%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Paul Jeng Guggenheim | Buy | Maintained | $52.00 | +64.2% | 11/03/2026 |
Leonid Timashev RBC Capital | Buy | Reiterated | $45.00 | +42.1% | 11/03/2026 |
Robert Driscoll Wedbush | Buy | Reiterated | $63.00 | +99% | 11/04/2026 |
Gregory Renza Truist Financial | Buy | Reiterated | $57.00 | +80% | 11/03/2026 |
Graig Suvannavejh Mizuho Securities | Buy | Maintained | $44.00 | +39% | 10/29/2026 |
Michael Yee UBS | Buy | Maintained | $50.00 | +57.9% | 10/26/2026 |
Anupam Rama J.P. Morgan | Buy | Maintained | - | - | 10/26/2026 |
Laura Prendergast Stifel Nicolaus | Buy | Maintained | $48.00 | +51.6% | 10/26/2026 |
Unknown Analyst Citi | Buy | Maintained | $65.00 | +105.3% | 10/26/2026 |
Yigal Nochomovitz Citi | Buy | Maintained | $65.00 | +105.3% | 10/26/2026 |
Unknown Analyst William Blair | Buy | Initiated | $51.00 | +61.1% | 10/15/2026 |
Sharon Zackfia William Blair | Buy | Initiated | $51.00 | +61.1% | 10/15/2026 |
Charles Zhu LifeSci Capital | Buy | Maintained | $58.00 | +83.2% | 09/27/2026 |
Silvan Turkcan Citizens JMP | Buy | Maintained | $42.00 | +32.7% | 08/06/2026 |
Eva Fortea Verdejo Wells Fargo | Buy | Maintained | $48.00 | +51.6% | 08/05/2026 |
Corinne Johnson Goldman Sachs | Hold | Maintained | $36.00 | +13.7% | 06/03/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | - | - | 05/05/2026 |
Unknown Analyst Goldman Sachs | Hold | Maintained | $35.00 | +10.5% | 04/14/2026 |
Unknown Analyst Wells Fargo | Buy | Maintained | $48.00 | +51.6% | 04/14/2026 |
Maury Raycroft Jefferies | Buy | Maintained | $52.00 | +64.2% | 04/05/2026 |
Last report
Nov 3, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$1.22 / -$1.16
-4.85%miss
arrow_downward
Revenue / Est. (USD)
10.24M / 7.58M
+35.08%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 207.83M | 10.88M | 6.56M | 8.86M |
Cost of goods sold | 82.99M | 86.60M | 95.73M | 108.69M |
Cost of revenue | 82.99M | 86.60M | 95.73M | 108.69M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 16.39M | 18.85M | 19.38M | 22.46M |
Operating expense | 16.39M | 18.85M | 19.38M | 22.46M |
Total operating expenses | 99.38M | 105.45M | 115.10M | 131.15M |
Operating income | 108.45M | -94.57M | -108.54M | -122.29M |
Other non operating income | - | - | - | - |
EBT including unusual items | 119.24M | -83.27M | -98.54M | -112.45M |
EBT excluding unusual items | 119.24M | -93.25M | -98.54M | -112.45M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | 119.24M | -83.27M | -98.54M | -112.45M |
Net profit margin | 57.37% | -765.66% | -1,502.12% | -1,269.64% |
Earnings per share | 1.33 | -0.94 | -1.11 | -1.22 |
Interest and investment income | 10.79M | 1.32M | 10.00M | 9.84M |
Interest expense | - | - | - | - |
Net interest expenses | 10.79M | 1.32M | 10.00M | 9.84M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 109.11M | -93.85M | -107.86M | -121.60M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events